Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

Fig. 7

Sitagliptin improves the response to anti-PD1 immunotherapy in a subgroup of HCC a. Schematic of sitagliptin and anti-PD1 treatments; b. Representative images of Hep1–6 tumors from each group; c. Tumor growth curves of Hep-1-6 tumors from each group; d. CD4 and CD8 immunohistochemistry staining of tumors treated with PBS, sitagliptin or anti-PD1 antibody. Left, representative pictures of IHC staining. Right, statistic of CD4+ and CD8+ T cells per section (n = 3); e. DPP4 activities in tumors treated with PBS, sitagliptin or/and anti-PD1 antibody; f. CD8 immunohistochemistry staining of HCC from patients with diabetes treated with or without sitagliptin. Left, representative pictures of CD8 IHC staining. Right, statistic of CD8+ T cells per patient

Back to article page

Molecular Cancer

ISSN: 1476-4598